![Song Jiang Ma](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Song Jiang Ma
Director Ejecutivo en Continent Pharmaceutical Inc. .
Cargos activos de Song Jiang Ma
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Director/Miembro de la Junta | 01/07/2002 | - |
Director Ejecutivo | 01/07/2002 | - | |
Beijing Jisheng Connor Network Technology Co. Ltd. | Director/Miembro de la Junta | - | - |
Corporate Officer/Principal | - | - | |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Director/Miembro de la Junta | 20/01/2022 | - |
Director Ejecutivo | 01/07/2011 | - | |
Corporate Officer/Principal | 01/07/2002 | 01/07/2011 |
Historial de carrera de Song Jiang Ma
Antiguos cargos conocidos de Song Jiang Ma.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CATALYST BIOSCIENCES | Director/Miembro de la Junta | 30/10/2023 | - |
Presidente | 30/10/2023 | - | |
Beijing Kangdini Factory | Fundador | 01/06/1996 | - |
Corporate Officer/Principal | 01/06/1996 | - | |
Beijing Jisheng Kangning Medical Technology Development | Director/Miembro de la Junta | - | - |
Beijing Kangqiang Economic & Technical Co. Ltd. | Director/Miembro de la Junta | - | - |
Beijing Institute of Telecommunication & Computer Applications | Director/Miembro de la Junta | - | - |
Formación de Song Jiang Ma.
China Electric Power Research Institute Ltd. | Graduate Degree |
Beijing University of Posts & Telecommunications | Undergraduate Degree |
Estadísticas
Internacional
China | 10 |
Estados Unidos | 2 |
Operativa
Director/Board Member | 8 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 8 |
---|---|
Continent Pharmaceutical Inc.
![]() Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
Beijing Jisheng Connor Network Technology Co. Ltd. | |
Beijing Institute of Telecommunication & Computer Applications | |
Beijing Jisheng Kangning Medical Technology Development | |
Beijing Kangqiang Economic & Technical Co. Ltd. | |
Beijing Kangdini Factory | |
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
Catalyst Biosciences, Inc.
![]() Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Song Jiang Ma
- Experiencia